ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RAPP vs OPK // EV/EBITDA & P/E VALUATION

Rapport Therapeutics Inc. (NASDAQ) VS. OPKO Health Inc. (NASDAQ) • 15-METRIC TALLY: RAPP 1 — OPK 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RAPP VS. OPK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RAPP OPK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 33.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -22.90% -10.20% -12.70 OPK /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -7.58% -14.41% +6.83 RAPP /fcf-yield <GO>
Operating Margin — -19.30% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -14.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 OPK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.7 58.9 -20.20 OPK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.20B $1.24B -$37.0M OPK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RAPP REV OPK REV RAPP GROSS % OPK GROSS % RAPP FCF OPK FCF
FY 2025 $350.3M $606.9M — 33.9% -$88.1M -$178.5M
FY 2024 $232.6M $713.1M — 30.6% -$67.2M -$183.5M
FY 2023 $101.3M $863.5M — — -$27.2M -$28.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RAPP // BETA —
OPK // BETA —